Hong Kong stock abnormal movement | Yisheng Biotechnology (01061.HK) surged more than 10% as its biological product license application for anti-VEGF ophthalmic injection has been accepted.

According to the Securities Times APP, Everest Medicines (01061.HK) surged more than 10%, as of the time of publication, up 9.39% to 5.94 Hong Kong dollars, with a turnover of 9.3261 million Hong Kong dollars.